Reports
Global Autism Spectrum Disorder Therapeutics Market Size, Share, Growth, Statistics, Report, Analysis, Forecast: By Disease Type: Autistic Disorder, Asperger’s Syndrome, Pervasive Development Disorder (PDD), Others; By Treatment Type; By Age Group; By Distribution Channel; Regional Analysis; Marker Dynamics; Supplier Landscape; 2023-2031
Global Autism Spectrum Disorder Therapeutics Market Outlook
The global autism spectrum disorder therapeutics market size attained a value of USD 1.99 billion in 2022, driven by the rising occurrences of ASD, increasing research and development aided by the government and industrial players, and growing pipeline of ASD drugs. The market is anticipated to grow at a CAGR of 6.7% during the forecast period of 2023-2031 to attain a value of USD 3.58 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Demand for Communication and Behavioural Therapies to Augment the Market Growth of ASD Therapeutics
Based on treatment type, the communication and behavioural therapies segment is expected to account for a significant share in the autism spectrum disorder therapeutics market. There is no cure for ASD, however, certain behavioural therapies can help reduce and manage problematic symptoms. Behavioural and speech language therapies aid in developing the patient’s social skills. Applied Behaviour Analysis (ABA) helps children with ASD learn how to communicate and play while diminishing troublesome behaviours. Research has shown that long term behavioural therapies has positively impacted children as well as adults with ASD.
The North American Region to Hold Substantial Share in the Market for Autism Spectrum Disorder Therapeutics
North America is expected to hold a significant share of the autism spectrum disorder therapeutics market during the forecast period, supported by increased number of ASD cases in the region. In 2021, the U.S. Food and Drug Administration authorised the marketing of Cognoa ASD Diagnosis Aid, a device to help diagnose autism spectrum disorder (ASD). The region is also characterised by research and development in the field of ASD which is expected to propel market growth during the forecast period. For instance, the National Institute of Mental Health headquartered in the USA, supports research focussed on the treatment and outcomes of autism spectrum disorder and related disorders.
Market Segmentation
Autism spectrum disorder (ASD) is a neurological development disability characterised with conditions such as anxiety, depression, and attention-deficit, hyperactivity, among others. ASD can begin at infancy and last throughout adulthood through a person’s life. ASD can be diagnosed based on behavioural patterns. ASD treatments are focussed on reducing the factors that interfere with people’s orderly functioning. Some of the drugs prescribed by the U.S. FDA include Risperidone and Aripiprazole for treating irritability associated with ASD.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By disease type, the market is divided into:
- Autistic Disorder
- Asperger’s Syndrome
- Pervasive Developmental Disorder (PDD)
- Others
Based on treatment type, the market can be segmented into:
- Communication and Behavioural Therapies
- Applied Behaviour Analysis (ABA)
- Speech and Language Therapy
- Occupational Therapy
- Others
- Drug Therapies
- Antipsychotic Drugs
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Stimulants
- Sleep Medications
- Others
The market is bifurcated based on age group into:
- Child
- Adult
On the basis of distribution channel, the market can be divided into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Number of Pipeline Drugs and Investment in Research and Development for the Treatment of ASD Expected to Propel Market Growth
The forecast period is expected to witness the development of drugs to treat ASD. The presence of a growing pipeline of ASD drugs and increasing research and development in this field is expected to boost the autism spectrum disorder therapeutics market during the forecast period. In 2022, STALICLA, a Swiss clinical stage biotech company announced the completion of the phase 1b trials for STP1. The trials allow the application of the company’s precision medicine discovery platform in ASD.
Over the forecast period, the rising number of ASD patients and the increasing awareness regarding the disease along with rising governmental initiatives is expected to encourage research in this area. Further, rapid technological advancements in medicine are expected to favour the market growth during the forecast period. Moreover, the adoption of behavioural therapies to overcome the communication gap in such patients is expected to further aid the market growth.
Key Players in the Global Market for Autism Spectrum Disorder Therapeutics
The report gives a detailed analysis of the following key players in the global autism spectrum disorder therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Neurim Pharmaceuticals, Inc.
- Q BioMed Inc.
- Hopebridge, LLC
- Yamo Pharmaceuticals LLC
- Curemark, LLC
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease type |
|
| Breakup by Treatment Type |
|
| Breakup by Age Group |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Autism Spectrum Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Autism Spectrum Disorder Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Autism Spectrum Epidemiology (2016-2031)
5.3 Europe Autism Spectrum Epidemiology (2016-2031)
5.4 Asia-Pacific Autism Spectrum Epidemiology (2016-2031)
5.5 Latin America Autism Spectrum Epidemiology (2016-2031)
5.6 Middle East & Africa Autism Spectrum Epidemiology (2016-2031)
6 Global Autism Spectrum Disorder Treatment Market Overview
6.1 Global Autism Spectrum Disorder Treatment Market Historical Value (2016-2022)
6.2 Global Autism Spectrum Disorder Treatment Market Forecast Value (2023-2031)
7 Global Autism Spectrum Disorder Treatment Market Landscape
7.1 Autism Spectrum Disorder Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Autism Spectrum Disorder Treatment: Product Landscape
7.2.1 Analysis by Disease Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Age Group
7.2.4 Analysis by Distribution Channel
8 Autism Spectrum Disorder Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Autism Spectrum Disorder Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Autism Spectrum Disorder Treatment Market Segmentation
11.1 Global Autism Spectrum Disorder Treatment Market by Disease type
11.1.1 Market Overview
11.1.2 Autistic Disorder
11.1.3 Asperger’s Syndrome
11.1.4 Pervasive Development Disorder (PDD)
11.1.5 Others
11.2 Global Autism Spectrum Disorder Treatment Market by Treatment Type
11.2.1 Market Overview
11.2.2 Communication and Behavioural Therapies
11.2.2.1 Applied Behaviour Analysis (ABA)
11.2.2.2 Speech and Language Therapy
11.2.2.3 Occupational Therapy
11.2.2.4 Others
11.2.3 Drug Therapies
11.2.3.1 Antipsychotic Drugs
11.2.3.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
11.2.3.3 Stimulants
11.2.3.4 Sleep Medications
11.2.3.5 Others
11.3 Global Autism Spectrum Disorder Treatment Market by Age Group
11.3.1 Market Overview
11.3.2 Child
11.3.3 Adult
11.3.4 Others
11.4 Global Autism Spectrum Disorder Treatment Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacies
11.4.3 Retail Pharmacies
11.4.4 Online Pharmacies
11.4.5 Others
11.5 Global Autism Spectrum Disorder Treatment Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Autism Spectrum Disorder Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Autism Spectrum Disorder Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Autism Spectrum Disorder Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Autism Spectrum Disorder Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Autism Spectrum Disorder Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Neurim Pharmaceuticals, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Q BioMed Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Hopebridge, LLC
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Yamo Pharmaceuticals LLC
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Curemark, LLC
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Bristol - Myers Squibb Company
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Merck & Co., Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Novartis AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Johnson & Johnson Services Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Eli Lilly and Company
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Yamo Pharmaceuticals
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 F. Hoffmann - La Roche Ltd.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Axial Therapeutics Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
24 Autism Spectrum Disorder Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2022, the global market for Autism Spectrum Disorder Therapeutics reached a value of USD 1.99 billion.
The market is anticipated to grow at a CAGR of 6.7% during the forecast period of 2023-2031 to reach a value of USD 3.58 billion by 2031.
The major drivers of the industry, such as the rising occurrences of ASD, increasing research and development aided by the government and industrial players, growing pipeline of ASD drugs, and rising focus on behavioural therapies, are expected to aid the market growth.
The key market trends include the increasing research and development to produce ASD drugs and rising awareness regarding ASD and its treatment.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The disease types covered in the report include autistic disorder, Asperger’s syndrome, and pervasive developmental disorder (PDD), among others.
The market is divided, based on treatment type, into communication and behavioural therapies and drug therapies.
The age groups considered in the market report include child and adult.
The various distribution channels in the market are hospital pharmacies, retail pharmacies, and online pharmacies.
The major players in the industry are Neurim Pharmaceuticals, Inc., Q BioMed Inc., Hopebridge, LLC, Yamo Pharmaceuticals LLC, and Curemark, LLC, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER